New antibody shows promise for Hard-to-Treat GVHD

NCT ID NCT03604692

Completed Disease control Sponsor: Syndax Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This trial tested a drug called axatilimab in 41 people with chronic graft-versus-host disease (cGVHD), a complication of stem cell transplants where donor cells attack the patient's body. Participants had already tried at least two other treatments. The study aimed to find a safe dose and see if the drug could improve symptoms. Results showed some patients had partial or complete responses, offering hope for a new treatment option.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: axatilimab (also called Niktimvo or SNDX-6352), an antibody that targets immune cells involved in chronic graft-versus-host disease
What this could lead to: If successful, axatilimab could offer a new treatment option for people with chronic graft-versus-host disease who have not responded to other therapies.
What could go wrong: This is an early-phase trial with only 41 participants, so results may not apply to everyone. Side effects and lack of lasting benefit are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT VERSUS HOST DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Bronchiolitis Obliterans Syndrome chronic graft versus host disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC GRAFT VERSUS HOST DISEASE

Contacts and locations

Locations

City of Hope

Duarte, California, 91010, United States
Fred Hutchinson Cancer Research Center

Seattle, Washington, 98109, United States
Indiana University Health Melvin and Bren Simon Cancer Center

Indianapolis, Indiana, 46202, United States
Karmanos Cancer Institute

Detroit, Michigan, 48201, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
University of Alabama at Birmingham

Birmingham, Alabama, 35294, United States
University of Miami Miller School of Medicine

Miami, Florida, 33136, United States
University of Minnesota Medical Center

Minneapolis, Minnesota, 55455, United States
University of Utah Health Huntsman Cancer Institute

Salt Lake City, Utah, 84112, United States
Vanderbilt-Ingram Cancer Center

Nashville, Tennessee, 37212-3505, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.